Upstream Bio Set to Unveil Phase 2 Asthma Trial Results for Verekitug
Event summary
- Upstream Bio to report top-line results from Phase 2 VALIANT trial of verekitug in severe asthma patients on February 11, 2026.
- Trial involved 478 patients randomized across four dose groups, including placebo, over a minimum of 24 weeks.
- Verekitug is the only known TSLP receptor antagonist in clinical development, targeting a validated inflammatory pathway.
- Results to be discussed via webcast at 8:00 a.m. ET, with replay available post-event.
The big picture
Upstream Bio's verekitug targets the TSLP pathway, a clinically validated driver of inflammatory diseases, positioning it as a potential breakthrough in severe respiratory disorders. The Phase 2 results will be critical in determining its competitive edge in a market dominated by biologics like dupilumab and tezepelumab. Success could expand its pipeline into other inflammatory conditions, while failure may necessitate a pivot in strategy.
What we're watching
- Clinical Efficacy
- Whether verekitug demonstrates superior efficacy over placebo in severe asthma patients, validating its TSLP receptor antagonism.
- Safety Profile
- The long-term safety data from the 60-week trial, particularly given the chronic nature of severe asthma.
- Development Pipeline
- How these results may accelerate or inform Upstream Bio's parallel Phase 2 trials in CRSwNP and COPD.
Related topics